By inhibiting SKIL expression in cancer cells, the adaptive immunity of tumor cells can be activated, thereby enhancing the efficacy of anti-tumor immunotherapy and introducing a novel treatment strategy for NSCLC. This evidence concerns the gene SKIL and neoplasm.